Vicore, Bioinvent and Hofseth all reported positive news today.
Vicore Pharma
Vicore Pharma is the global leader in Idiopathic pulmonary fibrosis (IPF). IPF is a condition in which the lungs become scarred, and breathing becomes increasingly difficult. Vicore has the best-ever results in their study. This year, the company is planning its 2B study, which may be used for the FDA approval.
Vicore Pharma announced this morning that they have signed an out-licensing deal for C21 in Japan. This is a strong deal that validates the potential for C21 in the IPF indication. The company received USD10m upfront and can receive an additional USD275m in milestones and royalties or 20%+ on sales in the end.
Nippon Shinyaku looks to be a strong partner in Japan. The Japanese market for IPF is relatively large, and Nippon Shinyaku already has a strong footprint within the rare respiratory disease market.
Nippon Shinyaku will be operationally and financially responsible for the future development of C21 in Japan.
Vicore trades at a fraction of market value vs the US peers, which have much worse results while being at the same stage of development. Vicore retained a new US-based CEO who is introducing the company to the US investors. The top US industry specialists have already invested.
Bringing US investors on board is low-hanging fruit. Last week, the company announced they’re attending the conferences below. this was not happening under the previous CEO. Big progress:
- Guggenheim 6th Annual Biotechnology Conference
Location: New York, NY.
Fireside Chat Date and Time: February 7 at 2:30 PM ET/ 8:30 PM CET.
Webcast Registration: Link - Oppenheimer 34th Annual Healthcare Life Sciences Conference
Presentation Date and Time: February 13 at 10:40 AM ET / 4:40 PM CET.
Webcast Registration: Link
BioInvent
| BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Bioinvent has: – 5 Projects in clinical development – 10+ Licensing, supply and collaboration agreements – 108 Employees (full-time equivalent) – 1,358 SEKm in liquid funds etc BioInvent today announced a clinical supply agreement with AstraZeneca to evaluate BioInvent’s antibody BI-1206. BI-1206 is one of BioInvent’s most advanced drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab, drugs with combined global sales of approximately USD 23 billion annually. The drug candidate is evaluated in two separate clinical programs, one for the treatment of non-Hodgkin’s lymphoma (NHL, a type of blood cancer) and one for the treatment of solid tumours. Two delivery formulations (intravenous (IV) and (subcutaneous (SC) of BI-1206 are being evaluated in parallel. Bioinvent announced today: – Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination study – BI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hodgkin’s lymphoma – The ongoing rituximab combination trial will be expanded to include the triplet arm Pareto analysts wrote today: “This increases the chance that BI-1206 will eventually reach the market, while also increasing the potential market itself. With BINV slowly but steadily growing while being well funded, we reiterate our Buy rating on BINV with a target price of SEK 134. ” Details: https://www.bioinvent.com/en/press/bioinvent-evaluate-bi-1206-combination-rituximab-and-calquence-2202100 |
Hofseth Biocare
Hofseth BioCare (HBC) is a high-tech tech, fully integrated business that takes off-cuts from salmon and produces high-value health nutritional products for people and pets. The company gradually transforms its portfolio into human health high margin products.
Hofseth Biocare today announced it delivered 80% revenue growth in 2023 vs 22. The company CEO issued positive guidance, saying they expect “further 50% revenue growth in 2024, higher capacity utilisation and positive EBITDA in 2024”
Full financials of HBC:
https://ml-eu.globenewswire.com/Resource/Download/159cccd4-13fe-4567-8862-ce5a6b959447
Norsk Titanium
Norsk Titanium (Euronext: NTI), a global leader in additive manufacturing for aerospace-grade structural titanium components using its patented Rapid Plasma Deposition® (RPD®) technology, announces development of Inconel 625 for US Navy applications.
NTI recently announced material progress in their cooperation with Airbus. Today NTI announced that under a contract with Bechtel Plant Machinery, Inc. (BPMI) Norsk Titanium has adapted their industrialized RPD® process for Inconel 625. As part of the ongoing effort, Norsk Titanium and BPMI are developing the deposition parameters and heat treatment process needed to produce additively manufactured Inconel 625 with material properties equivalent to legacy castings and forgings.
Inconel 625 is used in US Navy applications that require high strength and
resistance to corrosion. Bechtel Plant Machinery, Inc. is developing new
manufacturing processes for Inconel 625 to deliver cost and schedule savings to their customers as well as developing alternating sources of supply for crucial materials.
“This initial effort is an important first step in opening the nickel superalloy
market to our additive process,” said Nicholas Mayer Norsk Titanium Vice
President of Commercial. “We look forward to taking the learning from this
effort, and applying it to specific Naval applications,” added Mr. Mayer.
Norsk Titanium has recently announced qualification and production milestones in their core commercial aerospace titanium market. The addition of nickel superalloys and maritime applications is a key part of Norsk Titanium’s long term growth strategy.
Disclosure:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.
Fit Investment Ideas 